Tanezumab has advantages over Celebrex for osteoarthritic pain; report

16 May 2012

US rheumatologists and managed care organization (MCO) pharmacy directors survey by advisory firm Decision Resources agree that reduction in pain intensity is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in osteoarthritic pain.

Clinical data and the opinions of interviewed thought leaders indicate that Pfizer’s investigational compound tanezumab has advantages on this attribute over Pfizer’s Celebrex (celecoxib), the sales-leading agent for osteoarthritic pain.

A couple of years ago Pfizer suspended the osteoarthritis clinical program for the investigational compound tanezumab following a request by the US Food and Drug Administration (The Pharma Letter June 24, 2010). The worldwide suspension followed a small number of reports of tanezumab patients experiencing the worsening of osteoarthritis leading to joint replacement. However, trials of the drug continue in other pain indications.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK